NEW YORK, March 10, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease with an internal diversified pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, today announced that its petition for an O1A Visa ("Alien of Extraordinary Abilities") on behalf of Dr. Daniel G. Chain, Chairman & CEO, has been approved by the United States Citizenship and Immigration Services. Dr. Chain holds British and Israeli citizenship. Dr. Chain's petition was prepared and submitted by Wildes & Weinberg, P.C., a law firm specializing exclusively in the practice of U.S. immigration and nationality law.
